位于英格兰西米德兰兹区域的斯托克市，英国医学中心地处曼彻斯特与伯明翰之间，交通便利、医 疗资源集中。该中心将专注为欧洲地区口腔医生提供定制化正畸方案设计、病例分析及正畸技术支持， 并通过专业的医学团队，确保服务更贴近当地临床实践，符合监管标准。 未来，正雅英国团队将依托公司在隐形正畸与颌位重建领域二十余年的技术积累，结合欧洲市场的 临床需求，开发更具针对性的解决方案。同时，中心也将与当地口腔医疗机构及学术组织展开深入技术 研发与合作，共同推动隐形正畸技术的临床创新。 正雅创始人及CEO姚峻峰表示："英国是欧洲最具活力的医疗与科研市场之一。英国子公司与欧洲 医学中心的落成，不仅强化了我们的区域服务能力，也为更多欧洲医生与患者带来高质量的本地化支 持。未来，我们将继续以创新技术与精准医学为驱动力，助力全球医生提升诊疗效率，共同推动行业发 展。" 2025年9月，正雅齿科在全球布局中迈出重要一步——其位于英国特伦特河畔斯托克市（Stoke-on- Trent）的英国子公司兼欧盟医学中心正式投入运营，标志着正雅在欧洲市场的本地化战略进入全新阶 段，为区域合作医生提供更高效的正畸医学支持和服务。 该中心的成立，是正雅继 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [5]. Core Insights - The company achieved a revenue of $16.14 million in H1 2025, representing a year-on-year growth of 33.1%. Net profit reached $1.42 million, up 583.6%, while adjusted net profit was $1.95 million, growing by 84.8% [2]. - The rapid growth of overseas business has become a core driver, with revenue from global markets outside mainland China reaching $7.1 million, a 123% increase year-on-year. Domestic revenue slightly increased to $8.97 million. The total case count for H1 2025 was 225,800, up 47.7% [3]. - The company is focusing on enhancing R&D capabilities, increasing investments in IT, legal, and operational teams, optimizing legal services, expanding production capacity, and broadening its sales network to strengthen its global market presence [4]. Financial Performance Summary - The company forecasts net profits for 2025-2027 to be $1.2 million, $1.9 million, and $2.4 million, respectively, with growth rates of 1.85%, 53.03%, and 27.37%. The expected EPS for the same period is $0.072, $0.111, and $0.141, with corresponding P/E ratios of 133, 87, and 68 [5][9].